TC BioPharm Ltd（TCBP）股票分析

$0.500

-0.338 (-67.53%)收盤時

Loading chart…

High: 1.540
Open: 1.510
VWAP: 0.85
Vol: 5.90M
Mkt Cap: 4.10M
Low: 0.500
Amount: 4.99M
EV/EBITDA, TTM: 0.00

TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.

www.tcbiopharm.com

估值指標

The current forward P/E ratio for TC BioPharm Ltd (TCBP) is 0.00, compared to its 5-year average forward P/E of -0.46.

Forward P/E

Fair

5Y Average P/E

-0.46

Current P/E

0.00

高估

1.42

低估

-2.33

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

高估

0.00

低估

0.00

Forward P/S

Fair

5Y Average P/S

1.67

Current P/S

0.00

高估

4.86

低估

-1.53

事件時間軸

2025-11-18 (ET)

09:33:16

CytoMed finalizes purchase of TC BioPharm's T cell technology

2025-06-11 (ET)

08:32:58

TC Biopharm reports first patient remission in Cohort B after TCB008 treatment

2025-03-21 (ET)

10:46:52

TC Biopharm announces transition to OTC Markets from Nasdaq

2025-03-18 (ET)

08:08:03

TC Biopharm launches cost reduction initiatives

2025-03-05 (ET)

08:32:02

TC Biopharm executes non-binding LoI to acquire pharmaceutical company

Show More Events

資訊

TCBP FAQ — answered by Alphio AI

TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。